register_number stringlengths 11 11 | secondary_id listlengths 1 10 | url stringlengths 44 44 | brief_title stringlengths 20 290 | brief_summary stringlengths 63 5.05k | official_title stringlengths 25 483 ⌀ | intervention listlengths 1 19 | arm_intervention listlengths 1 21 ⌀ | f_condition listlengths 1 135 | sponsor listlengths 1 1 | collaborator listlengths 1 25 | experimental_drug listlengths 1 13 | study_identifier listlengths 1 7 ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NCT04204889 | [
{
"id_field": "org_study_id",
"id_value": [
"TOALS"
]
},
{
"id_field": "acronym",
"id_value": [
"TOALS"
]
}
] | https://clinicaltrials.gov/study/NCT04204889 | Trial of Oxaloacetate in ALS | The purpose of this study is to determine the safety and the maximal tolerated dose of Oxaloacetate (OAA) in patients with Amyotrophic Lateral Sclerosis (ALS). | Trial of Oxaloacetate in Amyotrophic Lateral Sclerosis | [
{
"description": "The first 3 patients will receive 500 mg twice daily, and subsequent cohorts will increase by 500 mg per dose to a maximum of 2500 mg twice daily.",
"name": "Oxaloacetic Acid",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Oxaloacetate"
],
"s... | [
{
"design_group_description": "3+3 dose escalating trial starting with 500mg twice daily orally and ending with 2500mg twice daily.",
"design_group_title": "Oxaloacetate",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": ... | [
"ALS"
] | [
"University of Kansas Medical Center"
] | [
"Terra Biological LLC"
] | [
[
{
"name": "Oxaloacetic Acid",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "TOALS"
}
] |
NCT05443425 | [
{
"id_field": "org_study_id",
"id_value": [
"22026"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2022-05061"
]
},
{
"id_domain": "City of Hope Medical Center",
... | https://clinicaltrials.gov/study/NCT05443425 | Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Transplant for Hematologic Malignancies | This phase I trial tests the safety and side effects of leflunomide in combination with steroids in treating patients with acute graft versus host disease who have undergone done stem cell transplant for blood cancers (hematologic malignancies). Sometimes the transplanted cells from a donor can attack the body's normal... | Pilot Trial of Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies | [
{
"description": "Given PO",
"name": "Cholestyramine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Cholybar",
"Colestyramine",
"Duolite AP143 Resin",
"Questran",
"Questran Light"
],
"type": "Drug"
},
{
"description": "Given PO... | [
{
"design_group_description": "Patients receive steroid therapy at the discretion of the treating physician. Beginning within 3 days of starting steroids, patients receive leflunomide PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity. Patients who respond to leflunomide treatment... | [
"Acute Graft Versus Host Disease",
"Hematopoietic and Lymphoid System Neoplasm"
] | [
"City of Hope National Medical Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "考来烯胺",
"lang": "CN"
},
{
"name": "Cholestyramine",
"lang": "EN"
},
{
"name": "コレスチラミン",
"lang": "JP"
}
],
[
{
"name": "来氟米特",
"lang": "CN"
},
{
"name": "Leflunomide",
"lang": "EN"
},
{
"nam... | null |
NCT00988624 | [
{
"id_field": "org_study_id",
"id_value": [
"B1451023"
]
}
] | https://clinicaltrials.gov/study/NCT00988624 | A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine) | This study will evaluate four different modified release formulation to estimate the amount of dimebon available to the body relative to the current dimebon formulation that is given three times a day. The results of this study will help inform and guide further formulation development efforts with the ultimate goal of... | A Phase 1, Randomized, Open-Label, Single Dose Cross-Over Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine) | [
{
"description": "Pharmacokinetics of a single oral dose of 10 mg dimebon immediate release tablet will be assessed on Day 1 - 3.",
"name": "Dimebon IR Tablet",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Pharmacokinetics of a single oral dose o... | [
{
"design_group_title": "Period 1",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Pharmacokinetics of a single oral dose of 10 mg dimebon immediate release tablet will be asse... | [
"Alzheimer's Disease",
"Huntington Disease"
] | [
"Pfizer Inc."
] | [
"MediVation, Inc."
] | [
[
{
"name": "盐酸地美波林",
"lang": "CN"
},
{
"name": "Dimebolin hydrochloride",
"lang": "EN"
}
]
] | null |
NCT02240407 | [
{
"id_field": "org_study_id",
"id_value": [
"IRB201400137"
]
},
{
"id_domain": "WIRB",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"20182574"
]
},
{
"id_field": "acronym",
"id_value": [
"AAV9-GAA_IM"
]
}
] | https://clinicaltrials.gov/study/NCT02240407 | Re-administration of Intramuscular AAV9 in Patients With Late-Onset Pompe Disease | A recombinant AAV vector has been generated to carry the codon-optimized acid alpha-glucosidase (coGAA) gene expressed from a human desmin enhancer/promoter (DES). The proposed clinical trial is a within-participant, double-blind, randomized, phase I controlled study evaluating the toxicology, biodistribution and poten... | Evaluation of Re-administration of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase (rAAV9-DES-hGAA) in Patients With Late-Onset Pompe Disease (LOPD) | [
{
"description": "The dose selected for this study is a fixed dose of 4.6 x 10^13 vg per TA muscle (range of 7.64 x 10^11 vg/gm to 4.6 x 10^11 vg/gm based on TA weight).",
"name": "Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase",
"normalized_type": "288887f0545745558ff1ab1c85757552",
"oth... | [
{
"design_group_description": "Each subject will receive Rituxan and Rapamycin prior to the initial exposure to the study agent in one leg and the subsequent exposure of the same vector to the contralateral leg after four months. Diphenhydramine and acetaminophen will be provided before each Rituxan dose. Immun... | [
"Pompe Disease"
] | [
"University of Florida"
] | [
"Lacerta Therapeutics, Inc."
] | [
[
{
"name": "对乙酰氨基酚",
"lang": "CN"
},
{
"name": "Acetaminophen",
"lang": "EN"
},
{
"name": "アセトアミノフェン",
"lang": "JP"
}
],
[
{
"name": "Recombinant adeno-associated virus acid alpha-glucosidase(University of Florida)",
"lang": "EN"
}... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "AAV9-GAA_IM"
}
] |
NCT03110640 | [
{
"id_field": "org_study_id",
"id_value": [
"20170316"
]
}
] | https://clinicaltrials.gov/study/NCT03110640 | Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma | This is a single-arm open-label phase I study to determine the effect of CD19- CAR-T Cells infusion followed by allogeneic stem cell transplantation in safety, efficacy and engraftment potential in patients with CD19+ B-lineage leukemia and lymphoma. | A Phase I Study of Administrating CD19 Chimeric Antigen Receptor Expressing T Cells Followed by Allogeneic Stem Cell Transplantation in Patients With Refractory CD19+ B-linage Leukemia/Lymphoma | [
{
"description": "Ex vivo-expanded autologous T cells modified to express CD19 CAR",
"name": "anti-CD19 CAR-T",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "Patients were given cyclophosphamide 500mg/m2/day on day -4 and fludarabine at 25 m... | [
{
"design_group_description": "All subjects will receive allogeneic stem cell transplantation after infusion of αCD19-TCRz-CD28 CAR-T",
"design_group_title": "CD9CAR-T transfer",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"interven... | [
"B-cell Adult Acute Lymphoblastic Leukemia",
"B-cell Chronic Lymphocytic Leukemia",
"Adult Acute Lymphoblastic Leukemia in Remission",
"Hematopoietic/Lymphoid Cancer",
"Refractory Chronic Lymphocytic Leukemia"
] | [
"The First Affiliated Hospital of Wenzhou Medical College"
] | [
"The Second Affiliated Hospital of Nanchang University",
"Hrain Biotechnology Co., Ltd."
] | [
[
{
"name": "磷酸氟达拉滨",
"lang": "CN"
},
{
"name": "Fludarabine Phosphate",
"lang": "EN"
},
{
"name": "フルダラビンリン酸エステル",
"lang": "JP"
}
],
[
{
"name": "环磷酰胺",
"lang": "CN"
},
{
"name": "Cyclophosphamide",
"lang": "EN"
... | null |
NCT01483846 | [
{
"id_field": "org_study_id",
"id_value": [
"VSG-CL-002"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R44DA018515"
]
}
] | https://clinicaltrials.gov/study/NCT01483846 | Safety, Tolerability and Pharmacokinetics of Multiple Doses of AV-101 in Healthy Volunteers | This is a Phase 1b study involving multiple oral doses of AV-101 in healthy male and female subjects. The safety, pharmacokinetics, and antihyperalgesic effect of AV-101 on capsaicin-induced hyperalgesia will be assessed. | A Phase 1b, Single-Site, Randomized, Double-Blind,Placebo-Controlled, Dose-Escalation Study: Safety, Pharmacokinetics, and Antihyperalgesic Activity of Multiple Doses of AV-101 on Capsaicin-Induced Pain in Healthy Volunteers | [
{
"description": "Placebo or AV-101 at 360 mg, 1080 mg, or 1440 mg will be dosed once daily for 14 consecutive days.",
"name": "AV-101",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"L-4-Cl-KYN"
],
"type": "Drug"
},
{
"description": "Placebo or AV-101 ... | [
{
"design_group_description": "Subjects will be randomized into one of three dose cohorts (360, 1,080, and 1,440 mg) to receive a daily oral dose for 14 consecutive days. Each cohort will have 12 subjects on active drug and 4 subjects on placebo.<br/>-------------------------------------------------------------... | [
"Neuropathic Pain"
] | [
"Vistagen Therapeutics, Inc."
] | [
"Cato Research LLC",
"National Institute on Drug Abuse"
] | [
[
{
"name": "4-Chlorokynurenine",
"lang": "EN"
}
]
] | null |
NCT05160545 | [
{
"id_field": "org_study_id",
"id_value": [
"GNC-035-103"
]
}
] | https://clinicaltrials.gov/study/NCT05160545 | A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer | In this study, the safety, tolerability and preliminary effectiveness of GNC-035 in participants with locally advanced or metastatic Breast Cancer will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum administered dose (MAD) for MTD is not reached of GNC-035. | An Open-Label, Multi-Center, Phase I Study I Study to Evaluate the Safety, Tolerability, Pharmacokinetic/Phamacodynamics and Anti-tumor Activity of Tetra-specific Antibody GNC-035 in Participants With Locally Advanced or Metastatic Breast Cancer | [
{
"description": "Administration by intravenous infusion",
"name": "GNC-035",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Patients receive GNC-035 intravenous infusion (IV, QW) for 2 weeks (a 2-week cycle). Participants with no intolerable AEs could continue for another three cycles",
"design_group_title": "GNC-035",
"design_group_type": "Experimental",
"design_group_type_normalized_id": ... | [
"Breast Cancer"
] | [
"Sichuan Baili Pharmaceuticals Co.,Ltd"
] | [
"Baili Bio Chengdu Pharmaceutical Co. Ltd."
] | [
[
{
"name": "GNC-035四特异性抗体(百利药业)",
"lang": "CN"
},
{
"name": "Nebratamig",
"lang": "EN"
}
]
] | null |
NCT06258304 | [
{
"id_field": "org_study_id",
"id_value": [
"GG-GIGA-564-001"
]
}
] | https://clinicaltrials.gov/study/NCT06258304 | A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies | The purpose of this study is to assess the safety and tolerability of GIGA-564 and identify the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) level(s) of GIGA-564 in participants with metastatic or locally advanced solid tumor malignancies. | A Phase 1 Dose Escalation and Expansion Study of GIGA-564, a Minimally Blocking Anti-CTLA-4 Monoclonal Antibody, in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies | [
{
"description": "Administered by intravenous infusion",
"name": "GIGA-564",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Administered by intravenous infusion",
"name": "GIGA-564",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
... | [
{
"design_group_description": "Up to 5 dose levels [0.3, 1.0, 3.0, 10.0, and 20.0 milligrams per kilogram (mg/kg)] will be evaluated sequentially. Participants will receive GIGA-564 intravenously over at least 60 minutes on Day 1 of every 3 weeks (3 weeks = 1 cycle) for up to 4 cycles until time of confirmed di... | [
"Advanced or Metastatic Solid Tumor Malignancies"
] | [
"GigaGen, Inc."
] | [
"National Cancer Institute"
] | [
[
{
"name": "GIGA-564",
"lang": "EN"
}
]
] | null |
NCT01273103 | [
{
"id_field": "org_study_id",
"id_value": [
"113393"
]
}
] | https://clinicaltrials.gov/study/NCT01273103 | A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2248761 Administered as an Oral Suspension to Healthy Adult Subjects | This study is a Phase I, open-label, single dose, mass balance study in a cohort of 6 healthy adult male subjects. The study will consist of: Screening evaluations, a treatment phase, and follow-up evaluations. In the treatment phase, after an overnight fast of at least 10 hours, each subject will receive a single oral... | An Open Label, Single Dose, Mass Balance Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2248761 200 mg, Administered as an Oral Suspension to Healthy Adult Subjects | [
{
"description": "single oral suspension dose of [14C]- GSK2248761 200 mg",
"name": "200mg [14C]- GSK2248761",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "[14C]- GSK2248761 200 mg",
"design_group_title": "Treatment",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "single oral suspension dose of [... | [
"Infection, Human Immunodeficiency Virus"
] | [
"ViiV Healthcare Ltd."
] | [
"GSK Plc"
] | [
[
{
"name": "Fosdevirine",
"lang": "EN"
}
]
] | null |
NCT03246659 | [
{
"id_field": "org_study_id",
"id_value": [
"GRAN-T-MTC"
]
},
{
"id_field": "acronym",
"id_value": [
"GRAN-T-MTC"
]
}
] | https://clinicaltrials.gov/study/NCT03246659 | Radiolabelled CCK-2/Gastrin Receptor Analogue for Personalized Theranostic Strategy in Advanced MTC | The study is a phase I multicentre randomized, open, parallel-arm clinical trial conducted to investigate the IMP, namely 111In-CP04.<br/>The study consists of preclinical (to establish a clinically useful formulation for the radiolabelled peptide CP04), and a clinical step. The main objective of the clinical part of t... | Phase I Clinical Trial Using a Novel CCK-2/Gastrin Receptor-localizing Radiolabelled Peptide Probe for Personalized Diagnosis and Therapy of Patients With Progressive or Metastatic Medullary Thyroid Carcinoma | [
{
"description": "Radiopharmaceutical preparation",
"name": "111In-CP04",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"111In-CP04 (DOTA-(DGlu)6-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2"
],
"type": "Drug"
},
{
"description": "Radiopharmaceutical preparation wit... | [
{
"design_group_description": "111In-CP04",
"design_group_title": "arm 1",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Radiopharmaceutical preparation",
"interve... | [
"Medullary Thyroid Carcinoma"
] | [
"Azienda Ospedaliero-Universitaria di Modena"
] | [
"Medical University of Innsbruck",
"Universitätsklinikum Freiburg",
"Erasmus Universitair Medisch Centrum Rotterdam",
"Uniwersytet Jagiellonski",
"UMC Ljubljana"
] | [
[
{
"name": "111In-CP-04",
"lang": "EN"
}
],
[
{
"name": "琥珀酰明胶",
"lang": "CN"
},
{
"name": "Succinylated Gelatin",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "GRAN-T-MTC"
}
] |
NCT02593370 | [
{
"id_field": "org_study_id",
"id_value": [
"AUH-TFB-SSPS"
]
}
] | https://clinicaltrials.gov/study/NCT02593370 | Suprasacral Parallel Shift - Ultrasound/MR Image Fusion Guided Lumbosacral Plexus Block | The main objective of the trial is to complete a double-blinded randomized controlled trial with crossover design of a lumbosacral plexus block with the Suprasacral Parallel Shift technique guided by ultrasound/magnetic resonance (MR) image fusion vs. Suprasacral Parallel Shift guided by ultrasound by estimating sensor... | null | [
{
"name": "Lidocaine-epinephrine added gadoterate meglumine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Use of ultrasound/MR image fusion guided Suprasacral Parallel Shift technique to place a lumbar plexus block (20 mL 2% lidocaine with epinephrine added gadoterate meglumine).",
"design_group_title": "Suprasacral Parallel Shift guided by US/MR image fusion",
"design_group_t... | [
"Hip Fractures",
"Anesthesia Local",
"Pain, Perioperative"
] | [
"Århus Universitetshospital"
] | [
"Århus Universitetshospital"
] | [
[
{
"name": "肾上腺素/盐酸利多卡因",
"lang": "CN"
},
{
"name": "Epinephrine/Lidocaine Hydrochloride",
"lang": "EN"
},
{
"name": "リドカイン塩酸塩/アドレナリン",
"lang": "JP"
}
],
[
{
"name": "钆特酸葡胺",
"lang": "CN"
},
{
"name": "Gadoterate Meglumin... | null |
NCT04447781 | [
{
"id_field": "org_study_id",
"id_value": [
"IVI COVID19-001"
]
}
] | https://clinicaltrials.gov/study/NCT04447781 | Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19 | This is a phase I/IIa trial to evaluate the safety, tolerability and immunological profile of INO-4800 administered by intradermal (ID) injection followed by electroporation (EP) using the CELLECTRA® 2000 device in healthy adults aged 19 to 64 years in Republic of Korea. INO- 4800 contains the plasmid pGX9501, which en... | A Phase I/IIa, Dose-Ranging Trial to Evaluate Safety, Tolerability and Immunogenicity of INO-4800, a Prophylactic Vaccine Against SARS-CoV-2, Administered Intradermally Followed by Electroporation in Healthy Volunteers | [
{
"description": "- Manufacturer: Inovio Pharmaceuticals Inc.",
"name": "INO-4800",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "- Manufacturer: Inovio Pharmaceuticals Inc.",
"name": "CELLECTRA® 2000",
"normalized_type": "63bce838d7... | [
{
"design_group_description": "* Number of Subjects: 20 subjects<br/>* ID Injection of INO-4800 1mg/dose + EP using CELLECTRA® 2000 (dosing at Day 0 and Week 4)",
"design_group_title": "Group 1 (Part A)",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f... | [
"Coronavirus Infection",
"SARS-CoV 2"
] | [
"International Vaccine Institute"
] | [
"Inovio Pharmaceuticals, Inc.",
"Coalition for Epidemic Preparedness Innovations"
] | [
[
{
"name": "INO-4800",
"lang": "EN"
}
]
] | null |
NCT03153202 | [
{
"id_field": "org_study_id",
"id_value": [
"GCO 17-0554"
]
}
] | https://clinicaltrials.gov/study/NCT03153202 | Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) | The purpose of this study is to determine the most appropriate dose for the combination of ibrutinib and pembrolizumab and to see if the combination is active for the disease. The study will monitor for any side effects and if the combination of ibrutinib and pembrolizumab works in the cancers being studied.<br/>There ... | Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) | [
{
"description": "once daily oral intake ibrutinib",
"name": "Ibrutinib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "200mg IV pembrolizumab on Day 1 of each cycle",
"name": "Pembrolizumab",
"normalized_type": "3d1aa88261d64c038413723970... | [
{
"design_group_description": "Participants with relapsed/ refractory Chronic Lymphocytic Leukemia (CLL) or 17p- CLL",
"design_group_title": "Participants with CLL",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
... | [
"Chronic Lymphocytic Leukemia",
"Mantle Cell Lymphoma"
] | [
"Icahn School of Medicine at Mount Sinai"
] | [
"Merck Sharp & Dohme Corp."
] | [
[
{
"name": "伊布替尼",
"lang": "CN"
},
{
"name": "Ibrutinib",
"lang": "EN"
},
{
"name": "イブルチニブ",
"lang": "JP"
}
],
[
{
"name": "帕博利珠单抗",
"lang": "CN"
},
{
"name": "Pembrolizumab",
"lang": "EN"
},
{
"name"... | null |
NCT03775538 | [
{
"id_field": "org_study_id",
"id_value": [
"HP-CD-CL-2003"
]
}
] | https://clinicaltrials.gov/study/NCT03775538 | Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease. Extension to HP-CD-CL-2002 Clinical Study | This study is an extension to the HP-CD-CL-2002 clinical study. It evaluates the long-term safety and tolerability of CDNF in patients with Parkinson's disease when dosed directly into the brain using an implanted investigational drug delivery system (DDS). Long-term safety of the DDS is also being evaluated. All patie... | A Randomised, Double-Blind, Multi-centre, Active Treatment, Extension and Safety Study for Patients With Idiopathic Parkinson's Disease (PD) Who Previously Completed the CDNF/DDS Main Study HP-CD-CL-2002 | [
{
"description": "Repeated intracerebral infusions",
"name": "Cerebral Dopamine Neurotrophic Factor",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"CDNF"
],
"type": "Drug"
},
{
"description": "Stereotactically implanted device",
"name": "Renishaw D... | [
{
"design_group_description": "Patients randomized to this group will receive 6 monthly-intermittent intracerebral doses of Cerebral Dopamine Neurotrophic Factor (CDNF) titrated to mid-dose (400 micrograms) administered via the Renishaw Drug Delivery System (DDS) to the bilateral putamen.",
"design_group_ti... | [
"Parkinson Disease",
"Movement Disorders",
"Neuro-Degenerative Disease",
"Nervous System Diseases",
"Brain Diseases"
] | [
"Herantis Pharma Oyj"
] | [
"Renishaw Plc"
] | [
[
{
"name": "Cerebral dopamine neurotrophic factor(University of Helsinki)",
"lang": "EN"
}
]
] | null |
NCT07164976 | [
{
"id_field": "org_study_id",
"id_value": [
"NCU-002-Ribo(M)"
]
}
] | https://clinicaltrials.gov/study/NCT07164976 | Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer | This document outlines an investigator-initiated Phase Ib/II clinical trial in Japan, focusing on the combination therapy of ribociclib and anastrozole for patients with hormone receptor-positive (HR-positive), HER2-negative metastatic or recurrent breast cancer. The trial aims to evaluate the efficacy (specifically, o... | Phase Ib/II Trial of Ribociclib Plus Anastrozole in Patients With Hormone Receptor-Positive, HER2-Negative Metastatic or Recurrent Breast Cancer | [
{
"description": "phase 1b cohort 1",
"name": "Ribociclib 400mg",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Phase 1b cohort 2",
"name": "Ribociclib 600mg",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
... | [
{
"design_group_description": "phase 1b cohort 1",
"design_group_title": "phase 1b cohort 1",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "phase 1b cohort 1",
"in... | [
"Breast Cancer"
] | [
"Nagoya City University"
] | [
"Novartis AG"
] | [
[
{
"name": "琥珀酸瑞波西利",
"lang": "CN"
},
{
"name": "Ribociclib Succinate",
"lang": "EN"
}
]
] | null |
NCT02291055 | [
{
"id_field": "org_study_id",
"id_value": [
"ADXS001-04"
]
}
] | https://clinicaltrials.gov/study/NCT02291055 | A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer | This was a multicenter, open-label, 2-part randomized study of MEDI4736 administered as monotherapy or in combination with ADXS11-001 to participants with recurrent/persistent or metastatic squamous or non-squamous carcinoma of the cervix or metastatic human papillomaviruses (HPV)+ squamous cell carcinoma of the head a... | Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combination In Previously Treated Locally Advanced or Metastatic Cervical or HPV+ Head & Neck Cancer | [
{
"name": "ADXS11-001",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"name": "MEDI4736",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Participants with cervical cancer received MEDI4736 3 milligrams per kilogram (mg/kg) intravenous (IV) infusion every 2 weeks (Q2W) at an infusion rate of approximately 60 minutes followed by ADXS11-001 1×10^9 CFU IV infusion every 4 weeks (Q4W) at an infusion rate of approximatel... | [
"Cervical Cancer",
"Cancer",
"Head and Neck Cancer"
] | [
"Advaxis, Inc."
] | [
"MedImmune LLC"
] | [
[
{
"name": "度伐利尤单抗",
"lang": "CN"
},
{
"name": "Durvalumab",
"lang": "EN"
},
{
"name": "デュルバルマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "Axalimogene filolisbac",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"code": "d358e55808ee2ee8e898223a58208a9a",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "dad0d98283aaa22ee82e4322205e3852",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "P24... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.